Matthias Riess

Prof. Matthias Riess

1. Anesthesiology, TVHS VA Medical Center, 1310 24th Avenue South, Nashville, TN 37212, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2012
Verified
Dataset
Closed access
Matthias RiessMatthias Riess
Matthias Riess
BACKGROUND: Bleeding during endoscopic sinus surgery (ESS) may increase complications and negatively effect the surgery and its outcome. The aim of this study was to compare the surgical field in patients in whom total intravenous anesthesia (TIVA) is used as opposed to inhalation anesthesia. A prospective randomized controlled trial was performed.METHODS: Fifty-six patients undergoing ESS were randomly assigned to receive either inhaled sevoflurane with incremental doses of fentanyl (n = 28) or TIVA via a propofol and remifentanil infusion (n = 28) for their general anesthesia. The surgical field was graded every 15 minutes using a validated scoring system.RESULTS: The two groups were matched for surgical procedure and computed tomography scores. Patients in the TIVA group were found to have a significantly lower surgical grade score than in the sevoflurane group (p < 0.001). Surgical grade score increased with time in both groups. Mean arterial pressure and pulse were found to influence the surgical field independently (p = 0.003 and p = 0.036 respectively). Mean surgical field grade scores were higher in the patients with allergic fungal sinusitis and nasal polyposis as opposed to chronic rhinosinusitis without polyps or fungus. Lund-Mackay computed tomography scores were found to correlate positively with surgical grade (Spearman rank correlation, p = 0.001).CONCLUSION: In patients undergoing ESS, TIVA results in a better surgical field than inhalational anesthesia.

20 January 2023 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
MNMaziar M. Nourian
Maziar M. Nourian
CSCosby A. Stone
Cosby A. Stone
KSKara K. Siegrist
Kara K. Siegrist
Matthias RiessMatthias Riess
Matthias Riess

20 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
Matthias RiessMatthias Riess
Matthias Riess
REReem Elorbany
Reem Elorbany
DWDorothee Weihrauch
Dorothee Weihrauch
DSDavid F. Stowe
David F. Stowe
Amadou K.S. CamaraAmadou K.S. Camara
Amadou K.S. Camara
The effect of anti-diabetic thiazolidinediones (TZDs) on contributing to heart failure and cardiac ischemia/reperfusion (IR) injury is controversial. In this study we investigated the effect of select TZDs on myocardial and mitochondrial function in Brown Norway rat isolated hearts. In a first set of experiments, the TZD rosiglitazone was given acutely before global myocardial IR, and pre- and post-IR function and infarct size were assessed. In a second set of experiments, different concentrations of rosiglitazone and pioglitazone were administered in the presence or absence of the specific PPARγ antagonist GW9662, and their effects on the mitochondrial redox state were measured by online NADH and FAD autofluorescence. The administration of rosiglitazone did not significantly affect myocardial function except for transiently increasing coronary flow, but it increased IR injury compared to the control hearts. Both TZDs resulted in dose-dependent, reversible increases in mitochondrial oxidation which was not attenuated by GW9662. Taken together, these data suggest that TZDs cause excessive mitochondrial uncoupling by a PPARγ-independent mechanism. Acute rosiglitazone administration before IR was associated with enhanced cardiac injury. If translated clinically, susceptible patients on PPARγ agonists may experience enhanced myocardial IR injury by mitochondrial dysfunction.

1 December 2014 in Resuscitation
Verified
Journal Article
Closed access
Matthias RiessMatthias Riess
Matthias Riess
TMTimothy R. Matsuura
Timothy R. Matsuura
JBJason A. Bartos
Jason A. Bartos
MBMartin Bienengraeber
Martin Bienengraeber
MAMohammed Aldakkak
Mohammed Aldakkak
DYDemetris Yannopoulos
Demetris Yannopoulos

19 October 2020 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
MSMichele M. Salzman
Michele M. Salzman
JBJason A. Bartos
Jason A. Bartos
DYDemetris Yannopoulos
Demetris Yannopoulos
Matthias RiessMatthias Riess
Matthias Riess
Reperfusion injury is a complex pathological event involving processes that can lead to further disruption of the cell membrane and function following an ischemic event. Return of blood flow allows for the needed reperfusion; however, for a period of time before remaining viable cells stabilize, reperfusion results in additional cellular injury. In cardiomyocytes, loss of membrane integrity allows abnormal influx of extracellular calcium, leading to hyper‐contracture and cell death. Methods to improve the membrane integrity of cardiomyocytes overwhelmed by pathological disruptions, such as reperfusion injury, are needed to prevent cell death, because of the myocardium's limited ability to regenerate. Research has shown administration of the copolymer P(oloxamer) 188 before ischemia/reperfusion can protect cardiomyocytes through membrane stabilization. This study sought to determine whether the administration of P188 at the beginning of the clinically more relevant time of reperfusion after ischemia will attenuate any additional damage to cardiomyocytes by stabilizing membrane integrity to allow the cells to maintain function. Using an in‐vitro cardiomyocyte model subjected to hypoxia/reoxygenation to simulate ischemia/reperfusion injury, we show that reoxygenation significantly potentiates the injury caused by hypoxia itself. P188, with its unique combination of hydrophobic and hydrophilic chemical properties, and only delivered at the beginning of reoxygenation, dose‐dependently protected cardiomyocytes from injury due to reoxygenation by repairing cell membranes, decreasing calcium influx, and maintaining cellular morphology. Our study also shows the hydrophobic portion of P188 is necessary for the stabilization of cell membrane integrity in providing protection to cardiomyocytes against reoxygenation injury.

26 May 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
SGSuneeta Gollapudy
Suneeta Gollapudy
DGDrake A. Gashkoff
Drake A. Gashkoff
DPDavid M. Poetker
David M. Poetker
TLTodd A. Loehrl
Todd A. Loehrl
Matthias RiessMatthias Riess
Matthias Riess